Free shipping on all orders over $ 500

JQ-1 carboxylic acid

Cat. No. M6096

All AbMole products are for research use only, cannot be used for human consumption.

JQ-1 carboxylic acid Structure
Synonym:

(+)-JQ-1 carboxylic acid

Size Price Availability Quantity
10mM*1mL in DMSO USD 70 In stock
1mg USD 35 In stock
5mg USD 64 In stock
10mg USD 86 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

JQ-1 carboxylic acid, a type of (+)-JQ-1 derivative, is a potent BET bromodomain inhibitor for downregulating PD-L1 expression on the surface of tumor cells. JQ-1 carboxylic acid can be used as a precursor to synthesize PROTACs, which targets BET bromodomains.

Protocol (for reference only)
Cell Experiment
Cell lines MC 11060 cells
Preparation method Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).
Concentrations ~500 nM
Incubation time 48 hours
Animal Experiment
Animal models Mice bearing NMC 797 xenografts
Formulation 5% DMSO in 5% dextrose
Dosages 50 mg/kg
Administration intraperitoneal injection
Chemical Information
Molecular Weight 400.88
Formula C19H17ClN4O2S
CAS Number 202592-23-2
Solubility (25°C) DMSO 30 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Kumar K, et al. Sci Rep. GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1.

[2] Lee DH, et al. Int J Cancer. Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.

Related Epigenetic Reader Domain Products
RVX-208

Apabetalone (RVX-208) is a first-in-class, small molecule inhibitor of BET bromodomain with IC50 of 0.51 μM for BD2.

I-BET151

I-BET151 (GSK1210151A) is an inhibitor of the BET family with IC50 of 0.5 μM, 0.25 μM and 0.79 μM for BRD2, BRD3 and BRD4, respectively.

(+)-JQ1

(+)-JQ1 is a BET bromodomain inhibitor that acts on BRD4(2) with an IC50 of 33 nM and binds to all bromodomain domains in the BET family, but not to bromodomain domains outside the BET family. JQ1 down-regulates CD47 expression through a C-MYC-mediated pathway, and JQ1 down-regulates CD47 expression through a C-MYC-mediated pathway.

I-BET-762

I-BET-762 (GSK525762) is a selective small molecule BET inhibitor.

CPI-0610

CPI-0610 is a novel BET protein bromodomain inhibitor.

  Catalog
Abmole Inhibitor Catalog




Keywords: JQ-1 carboxylic acid, (+)-JQ-1 carboxylic acid supplier, Epigenetic Reader Domain, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.